CAR T-cell therapy for high-risk smoldering myeloma
Part of Cancer clinical trials.
This trial tests a new CAR T-cell therapy (cilta-cel) for people with high-risk smoldering multiple myeloma. It aims to prevent progression to active myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have high-risk smoldering multiple myeloma (a type of very early, active myeloma).
- You are able to do your normal daily activities with little or no help (ECOG score 0 or 1).
- Your kidneys work well enough (estimated GFR at least 40 mL/min).
- Your blood counts (hemoglobin, white blood cells, and platelets) are stable and at minimum levels – no recent transfusions needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This trial tests a new medicine called a BCMA/CD3 bispecific antibody for people with a very early form of multiple myeloma called high-risk smoldering myeloma. The goal is to see if this treatment can stop the disease from getting worse.
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This trial tests an investigational CAR-T cell therapy (anitocabtagene autoleucel) in people with newly diagnosed multiple myeloma. It aims to see if this treatment is safe and effective when given after a short course of standard chemotherapy.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Hear when a new High Risk Smoldering Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.